mitoxantrone has been researched along with Vomiting in 29 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double-blind clinical trial of mitoxantrone versus methylprednisolone was performed in 49 patients with relapsing, secondary multiple sclerosis." | 9.09 | A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. ( Beguin, C; Carton, H; D'Hooghe, MB; Dooms, G; Lissoir, F; Sindic, CJ; van de Wyngaert, FA, 2001) |
| "We investigated the antiemetic effect, safety and usefulness of granisetron tablet on nausea/vomiting induced by cytosine arabinoside (Ara-C) in the chemotherapy for tumors in the hematopoietic organs." | 9.07 | [Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs]. ( Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K, 1993) |
| "As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 9.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
| "A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)." | 7.68 | Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 7.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "The therapeutic effects of 4'-Epi-Adriamycin (Epi-ADR), THP-Adriamycin (THP-ADR) and Mitoxantrone on 30 patients with advanced and recurrent breast cancer were analyzed." | 7.67 | [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1984) |
| "Mitoxantrone was evaluated in a multi-institution trial to define the effective dose for treating acute leukemia, to evaluate its toxicity, and to assess the induction rates for the different types of acute leukemia." | 7.67 | Phase I-II trial of mitoxantrone in acute leukemia. ( Arlin, ZA; Armentrout, S; Cassileth, P; Coleman, M; Daghestani, A; Dukart, G; Gams, R; Schoch, I; Silver, R, 1985) |
| "Twenty-three patients with advanced breast cancer were treated with the combination of mitoxantrone and doxorubicin." | 7.67 | Combined mitoxantrone plus doxorubicin in the treatment of breast cancer. ( Lefebvre, BM; Maroun, JA; Perrault, DJ; Stewart, DJ, 1987) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 7.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
| "Forty-two women with measurable or evaluable advanced breast cancer who had received neither prior chemotherapy for advanced disease nor any anthracycline-containing regimen as adjuvant were entered in a phase II study of mitoxantrone (Novantrone; dihydroxyanthracenedione)." | 7.67 | Mitoxantrone as a first-line treatment of advanced breast cancer. ( Andersson, T; Borgstrom, S; Landys, K; Noppa, H, 1985) |
| "Congestive heart failure has been observed in one patient (doxorubicin)." | 6.66 | A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985) |
| "Mitoxantrone was subsequently given in a five-day schedule at a dose of 10mg/m2 daily to twenty-one patients with relapsed or refractory acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC)." | 6.66 | Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. ( Prentice, HG; Robbins, G; Wimperis, JZ, 1985) |
| "Mitoxantrone was well tolerated with myelosuppression as the dose-limiting toxicity." | 5.27 | Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. ( Coleman, R; Cornbleet, M; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, R; Smith, I; Smyth, J; Stuart-Harris, R; van Oosterom, A, 1985) |
| "Mitoxantrone is a synthetic aminoanthraquinone we have previously reported to be effective for patients with acute leukemia in relapse." | 5.27 | Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. ( Cuttner, J; Dutcher, JP; Holland, JF; Paciucci, PA; Strauman, JJ; Wiernik, PH, 1987) |
| "A double-blind clinical trial of mitoxantrone versus methylprednisolone was performed in 49 patients with relapsing, secondary multiple sclerosis." | 5.09 | A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. ( Beguin, C; Carton, H; D'Hooghe, MB; Dooms, G; Lissoir, F; Sindic, CJ; van de Wyngaert, FA, 2001) |
| "We investigated the antiemetic effect, safety and usefulness of granisetron tablet on nausea/vomiting induced by cytosine arabinoside (Ara-C) in the chemotherapy for tumors in the hematopoietic organs." | 5.07 | [Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs]. ( Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K, 1993) |
| "As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 5.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
| " Prior to overt cerebral invasion by NHL, she had a thiamine deficiency with very low thiamine concentrations in the CSF, probably caused by protracted vomiting and increased vitamin B1 consumption by intrathecal tumor cells." | 3.70 | Downbeat nystagmus caused by thiamine deficiency: an unusual presentation of CNS localization of large cell anaplastic CD 30-positive non-Hodgkin's lymphoma. ( Boerman, RH; Mattijssen, V; Mulder, AH; Raemaekers, JM, 1999) |
| "A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)." | 3.68 | Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 3.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
| "Mitoxantrone was evaluated in a multi-institution trial to define the effective dose for treating acute leukemia, to evaluate its toxicity, and to assess the induction rates for the different types of acute leukemia." | 3.67 | Phase I-II trial of mitoxantrone in acute leukemia. ( Arlin, ZA; Armentrout, S; Cassileth, P; Coleman, M; Daghestani, A; Dukart, G; Gams, R; Schoch, I; Silver, R, 1985) |
| "Forty-two women with measurable or evaluable advanced breast cancer who had received neither prior chemotherapy for advanced disease nor any anthracycline-containing regimen as adjuvant were entered in a phase II study of mitoxantrone (Novantrone; dihydroxyanthracenedione)." | 3.67 | Mitoxantrone as a first-line treatment of advanced breast cancer. ( Andersson, T; Borgstrom, S; Landys, K; Noppa, H, 1985) |
| "Twenty-three patients with advanced breast cancer were treated with the combination of mitoxantrone and doxorubicin." | 3.67 | Combined mitoxantrone plus doxorubicin in the treatment of breast cancer. ( Lefebvre, BM; Maroun, JA; Perrault, DJ; Stewart, DJ, 1987) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 3.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "The therapeutic effects of 4'-Epi-Adriamycin (Epi-ADR), THP-Adriamycin (THP-ADR) and Mitoxantrone on 30 patients with advanced and recurrent breast cancer were analyzed." | 3.67 | [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1984) |
| "Infections were the cause of death in nine patients, including four in the CMC5 group and five in the CMC3 group." | 2.70 | Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. ( Boguradzki, P; Błoński, JZ; Calbecka, M; Ceglarek, B; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Góra-Tybor, I; Kasznicki, M; Konopka, L; Kuliczkowski, K; Moskwa-Sroka, B; Nowak, W; Robak, T; Skotnicki, AB; Stella-Hołowiecka, B; Sułek, J; Wołowiec, D, 2001) |
| " Ten dogs were given mitoxantrone at a dosage of 5." | 2.67 | Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study. ( Atwater, SW; Bergman, PJ; Chen, C; Ciekot, PA; Moore, AS; Ogilvie, GK; Walters, LM, 1994) |
| "Mitoxantrone has demonstrable clinical activity when administered intravenously in a wide range of malignancies." | 2.67 | Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. ( Aartsen, E; Dubbelman, R; Mandjes, I; McVie, JG; Oza, AM; Soepenberg, O; ten Bokkel Huinink, W, 1994) |
| "Thirty children with refractory acute lymphocytic leukemia (ALL) were treated with mitoxantrone, 8 mg/m2/day, for 5 days." | 2.67 | Phase II trial of mitoxantrone in acute lymphocytic leukemia of childhood. A Pediatric Oncology Group study. ( Estrada, J; Graham, ML; Ragab, AH; Rosen, D; Starling, KA; Wilkenson, RW; Wilkerson, RW, 1991) |
| " every 3 weeks in escalating doses combined with a fixed dose of s." | 2.67 | Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors. ( Dal Fior, S; Favretto, S; Gasparini, G; Panizzoni, GA; Pozza, F; Von Hoff, DD, 1991) |
| "Mitoxantrone (Novantrone), is an anthracenedione which in preclinical studies demonstrated a spectrum of antitumor activity similar to the anthracyclines, but with less cardiotoxicity." | 2.66 | Mitoxantrone: an overview of safety and toxicity. ( Bernstein, T; Cartwright, K; Dukart, G; Goldberg, J; Posner, LE, 1985) |
| "Congestive heart failure has been observed in one patient (doxorubicin)." | 2.66 | A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985) |
| "Mitoxantrone was subsequently given in a five-day schedule at a dose of 10mg/m2 daily to twenty-one patients with relapsed or refractory acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC)." | 2.66 | Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. ( Prentice, HG; Robbins, G; Wimperis, JZ, 1985) |
| " Although the primary purpose of this study was to determine a clinically useful dosage and to characterize the toxicoses associated with mitoxantrone administration, each cat was monitored for response to treatment." | 1.29 | Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors. ( Atwater, SW; Ciekot, PE; Elmslie, RE; Klein, MK; Moore, AS; Obradovich, JE; Ogilvie, GK; Salmon, MD; Straw, RC; Vail, DM, 1993) |
| "To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m2 in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C)." | 1.27 | Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C). ( Civin, CI; Krischer, J; Land, VJ; Ragab, AH; Steuber, CP; Vietti, TJ, 1987) |
| "Mitoxantrone is a synthetic aminoanthraquinone we have previously reported to be effective for patients with acute leukemia in relapse." | 1.27 | Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. ( Cuttner, J; Dutcher, JP; Holland, JF; Paciucci, PA; Strauman, JJ; Wiernik, PH, 1987) |
| "Mitoxantrone was well tolerated with myelosuppression as the dose-limiting toxicity." | 1.27 | Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. ( Coleman, R; Cornbleet, M; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, R; Smith, I; Smyth, J; Stuart-Harris, R; van Oosterom, A, 1985) |
| "Ametantrone was extensively distributed (apparent volume of distribution, 26." | 1.27 | A phase I trial of ametantrone acetate (NSC-287513). ( Bender, JF; Gams, RA; Grillo-López, AJ; Ostroy, F, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (51.72) | 18.7374 |
| 1990's | 11 (37.93) | 18.2507 |
| 2000's | 3 (10.34) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tominaga, T | 1 |
| Kitamura, M | 1 |
| Hayashi, K | 1 |
| Takahashi, I | 1 |
| Kosaki, G | 1 |
| Sonneveld, P | 1 |
| de Ridder, M | 1 |
| van der Lelie, H | 1 |
| Nieuwenhuis, K | 1 |
| Schouten, H | 1 |
| Mulder, A | 1 |
| van Reijswoud, I | 1 |
| Hop, W | 1 |
| Lowenberg, B | 1 |
| Ogilvie, GK | 3 |
| Moore, AS | 3 |
| Chen, C | 1 |
| Ciekot, PA | 1 |
| Atwater, SW | 2 |
| Bergman, PJ | 1 |
| Walters, LM | 1 |
| Oza, AM | 1 |
| ten Bokkel Huinink, W | 1 |
| Dubbelman, R | 1 |
| Soepenberg, O | 1 |
| Mandjes, I | 1 |
| Aartsen, E | 1 |
| McVie, JG | 1 |
| Obradovich, JE | 2 |
| Elmslie, RE | 2 |
| Vail, DM | 2 |
| Straw, RC | 2 |
| Salmon, MD | 1 |
| Klein, MK | 1 |
| Ciekot, PE | 1 |
| Matsuishi, H | 1 |
| Harada, M | 1 |
| Gondo, H | 1 |
| Otsuka, T | 1 |
| Teshima, T | 1 |
| Yamano, Y | 1 |
| Omori, F | 1 |
| Shibuya, T | 1 |
| Yamazaki, K | 1 |
| Taniguchi, S | 1 |
| Mulder, AH | 1 |
| Raemaekers, JM | 1 |
| Boerman, RH | 1 |
| Mattijssen, V | 1 |
| Thurnher, D | 1 |
| Kornfehl, J | 1 |
| Burian, M | 1 |
| Gedlicka, C | 1 |
| Selzer, E | 1 |
| Quint, C | 1 |
| Neuchrist, C | 1 |
| Kornek, GV | 1 |
| Robak, T | 1 |
| Błoński, JZ | 1 |
| Kasznicki, M | 1 |
| Góra-Tybor, I | 1 |
| Dwilewicz-Trojaczek, J | 1 |
| Boguradzki, P | 1 |
| Konopka, L | 1 |
| Ceglarek, B | 1 |
| Sułek, J | 1 |
| Kuliczkowski, K | 1 |
| Wołowiec, D | 1 |
| Stella-Hołowiecka, B | 1 |
| Skotnicki, AB | 1 |
| Nowak, W | 1 |
| Moskwa-Sroka, B | 1 |
| Dmoszyńska, A | 1 |
| Calbecka, M | 1 |
| van de Wyngaert, FA | 1 |
| Beguin, C | 1 |
| D'Hooghe, MB | 1 |
| Dooms, G | 1 |
| Lissoir, F | 1 |
| Carton, H | 1 |
| Sindic, CJ | 1 |
| Gasparini, G | 1 |
| Dal Fior, S | 1 |
| Pozza, F | 1 |
| Panizzoni, GA | 1 |
| Favretto, S | 1 |
| Von Hoff, DD | 2 |
| Graham, ML | 1 |
| Estrada, J | 1 |
| Ragab, AH | 2 |
| Starling, KA | 1 |
| Rosen, D | 1 |
| Wilkenson, RW | 1 |
| Wilkerson, RW | 1 |
| Samonigg, H | 1 |
| Stöger, H | 1 |
| Kasparek, AK | 1 |
| Schmid, M | 1 |
| Dusleag, J | 1 |
| Pfeiffer, K | 1 |
| Smola, M | 1 |
| Steindorfer, P | 1 |
| Lechner, P | 1 |
| Curtis, CR | 1 |
| Dickinson, K | 1 |
| Cooper, MF | 1 |
| Withrow, SJ | 1 |
| Hiddemann, W | 1 |
| Büchner, T | 1 |
| Heil, G | 1 |
| Schumacher, K | 1 |
| Diedrich, H | 1 |
| Maschmeyer, G | 1 |
| Ho, AD | 1 |
| Planker, M | 1 |
| Gerith-Stolzenburg, S | 1 |
| Donhuijsen-Ant, R | 1 |
| Martoni, A | 2 |
| Rani, P | 1 |
| Ercolino, L | 1 |
| Canova, N | 1 |
| Pannuti, F | 2 |
| Paciucci, PA | 1 |
| Dutcher, JP | 1 |
| Cuttner, J | 1 |
| Strauman, JJ | 1 |
| Wiernik, PH | 1 |
| Holland, JF | 1 |
| Steuber, CP | 1 |
| Land, VJ | 1 |
| Civin, CI | 1 |
| Krischer, J | 1 |
| Vietti, TJ | 1 |
| Stewart, DJ | 1 |
| Perrault, DJ | 1 |
| Maroun, JA | 1 |
| Lefebvre, BM | 1 |
| Arlin, ZA | 1 |
| Silver, R | 1 |
| Cassileth, P | 1 |
| Armentrout, S | 1 |
| Gams, R | 1 |
| Daghestani, A | 1 |
| Coleman, M | 1 |
| Schoch, I | 1 |
| Dukart, G | 2 |
| Posner, LE | 1 |
| Goldberg, J | 1 |
| Bernstein, T | 1 |
| Cartwright, K | 1 |
| Cowan, JD | 1 |
| Osborne, CK | 1 |
| Neidhart, JA | 1 |
| Constanzi, JJ | 1 |
| Vaughn, CB | 1 |
| Bennett, JM | 1 |
| Byrne, P | 1 |
| Desai, A | 1 |
| White, C | 1 |
| DeConti, R | 1 |
| Vogel, C | 1 |
| Krementz, E | 1 |
| Muggia, F | 1 |
| Doroshow, J | 1 |
| Plotkin, D | 1 |
| Prentice, HG | 1 |
| Wimperis, JZ | 1 |
| Robbins, G | 1 |
| Landys, K | 1 |
| Borgstrom, S | 1 |
| Andersson, T | 1 |
| Noppa, H | 1 |
| Mouridsen, HT | 1 |
| Cornbleet, M | 1 |
| Stuart-Harris, R | 1 |
| Smith, I | 1 |
| Coleman, R | 1 |
| Rubens, R | 1 |
| McDonald, M | 1 |
| Rainer, H | 1 |
| van Oosterom, A | 1 |
| Smyth, J | 1 |
| Metz, R | 1 |
| Delgado, M | 1 |
| Keiling, R | 1 |
| Cappelaere, P | 1 |
| Armand, JP | 1 |
| Prevot, G | 1 |
| Misset, JL | 1 |
| Grimbert, J | 1 |
| Mathe, G | 1 |
| Periti, P | 1 |
| della Cuna, GR | 1 |
| Mazzei, T | 1 |
| Preti, P | 1 |
| Mini, E | 1 |
| Gams, RA | 1 |
| Ostroy, F | 1 |
| Bender, JF | 1 |
| Grillo-López, AJ | 1 |
13 trials available for mitoxantrone and Vomiting
| Article | Year |
|---|---|
Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1995 |
Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study.
Topics: Animals; Bone Marrow; Diarrhea; Dog Diseases; Dogs; Female; Follow-Up Studies; Leukocyte Count; Logi | 1994 |
Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer.
Topics: Abdominal Pain; Female; Hematologic Diseases; Humans; Injections, Intraperitoneal; Middle Aged; Mito | 1994 |
[Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyta | 1993 |
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cladribine; Cohort Stud | 2001 |
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
Topics: Adult; Alopecia; Contrast Media; Double-Blind Method; Female; Follow-Up Studies; Gadolinium; Humans; | 2001 |
Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relation | 1991 |
Phase II trial of mitoxantrone in acute lymphocytic leukemia of childhood. A Pediatric Oncology Group study.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Drug Evaluation; Female; Humans; | 1991 |
Mitoxantrone: an overview of safety and toxicity.
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Clini | 1985 |
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Topics: Adult; Aged; Alopecia; Anthracenes; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinica | 1985 |
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; | 1985 |
Sequential studies on the role of mitoxantrone in the treatment of acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Agranulocytosis; Anthraquinones; Antineoplastic Agents; Bone | 1985 |
16 other studies available for mitoxantrone and Vomiting
| Article | Year |
|---|---|
[Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Mi | 1984 |
Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors.
Topics: Animals; Anorexia; Carcinoma, Squamous Cell; Cat Diseases; Cats; Chemotherapy, Adjuvant; Dose-Respon | 1993 |
Downbeat nystagmus caused by thiamine deficiency: an unusual presentation of CNS localization of large cell anaplastic CD 30-positive non-Hodgkin's lymphoma.
Topics: Adult; Anisocoria; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Bleomycin; Brain Neoplas | 1999 |
Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distributi | 1991 |
Toxicoses associated with administration of mitoxantrone to dogs with malignant tumors.
Topics: Animals; Anorexia; Bone Marrow; Diarrhea; Dog Diseases; Dogs; Female; Lymphoma; Male; Mitoxantrone; | 1991 |
Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1990 |
Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1988 |
Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Diarrhea; Drug Administrati | 1987 |
Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Hea | 1987 |
Combined mitoxantrone plus doxorubicin in the treatment of breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Breast | 1987 |
Phase I-II trial of mitoxantrone in acute leukemia.
Topics: Acute Disease; Adult; Aged; Anthraquinones; Drug Evaluation; Female; Heart; Humans; Leukemia; Leukem | 1985 |
Mitoxantrone as a first-line treatment of advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Cardiac Output; Female; Heart; | 1985 |
Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Drug Ev | 1985 |
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cycloph | 1985 |
First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1985 |
A phase I trial of ametantrone acetate (NSC-287513).
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Marrow; Drug Administration Schedule; Drug | 1985 |